Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Preliminary Report of Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical Application

Ebru Erdogan, View ORCID ProfileKoray Yalcin, Cansu Hemsinlioglu, Aslihan Sezgin, Utku Seyis, Derya Dilek Kancagi, Cihan Tastan, Bulut Yurtsever, Raife Dilek Turan, Didem Cakirsoy, Selen Abanuz, Gozde Sir Karakus, Muhammer Elek, Huseyin Saffet Bekoz, Ali İhsan Gemici, Deniz Sargin, Mutlu Arat, Burhan Ferhanoglu, Ebru Pekguc, Serdar Ornek, Deram Buyuktas, Nur Birgen, Siret Ratip, Ercument Ovali
doi: https://doi.org/10.1101/2021.09.23.21263731
Ebru Erdogan
1Acıbadem Altunizade Hospital Hematology Unit, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koray Yalcin
2Acıbadem Labcell Cellular Therapy Center, Istanbul
3Bahcesehir University Medical Park Goztepe Hospital Pediatric Bone Marrow Transplantation Unit, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Koray Yalcin
  • For correspondence: koray.ylc@gmail.com
Cansu Hemsinlioglu
2Acıbadem Labcell Cellular Therapy Center, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Aslihan Sezgin
1Acıbadem Altunizade Hospital Hematology Unit, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Utku Seyis
2Acıbadem Labcell Cellular Therapy Center, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derya Dilek Kancagi
2Acıbadem Labcell Cellular Therapy Center, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cihan Tastan
2Acıbadem Labcell Cellular Therapy Center, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bulut Yurtsever
2Acıbadem Labcell Cellular Therapy Center, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raife Dilek Turan
2Acıbadem Labcell Cellular Therapy Center, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Didem Cakirsoy
2Acıbadem Labcell Cellular Therapy Center, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Selen Abanuz
2Acıbadem Labcell Cellular Therapy Center, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gozde Sir Karakus
2Acıbadem Labcell Cellular Therapy Center, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Muhammer Elek
2Acıbadem Labcell Cellular Therapy Center, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Huseyin Saffet Bekoz
4Medipol University School of Medicine Hematology Unit, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ali İhsan Gemici
4Medipol University School of Medicine Hematology Unit, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deniz Sargin
4Medipol University School of Medicine Hematology Unit, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mutlu Arat
5Istanbul Florence Nightingale Hospital Hematology Unit, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Burhan Ferhanoglu
6VKV American Hospital Hematology Unit, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ebru Pekguc
6VKV American Hospital Hematology Unit, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Serdar Ornek
6VKV American Hospital Hematology Unit, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deram Buyuktas
6VKV American Hospital Hematology Unit, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nur Birgen
2Acıbadem Labcell Cellular Therapy Center, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Siret Ratip
1Acıbadem Altunizade Hospital Hematology Unit, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ercument Ovali
2Acıbadem Labcell Cellular Therapy Center, Istanbul
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objective Chimeric antigen receptor T (CAR-T) cell therapies already made an impact on the treatment of B cell malignancies. Although CAR-T cell therapies are promising, there are concerns with commercial products regarding their affordability and sustainability. In this preliminary study, results of the first productional and clinical data of academic CAR-T cell (ISIKOK-19) from Turkey are presented.

Materials and Methods A pilot clinical trial (NCT04206943) designed to assess the safety and feasibility of ISIKOK-19 T-cell therapy in patients with relapsed and refractory CD19+ tumors was conducted and participating patients received ISIKOK-19 infusions between October 2019 and July 2021. Production data of the first 8 patients and the clinical outcome of 7 patients who received ISIKOK-19 cell infusion is presented in this study.

Results Nine patients were enrolled for the trial (ALL n=5 and NHL n=4) but only 7 patients could receive the treatment. Two out of three ALL patients and three out of four NHL patients had complete/partial response (ORR 72%). Four patients (57%) had CAR-T-related toxicities (CRS, CRES, and pancytopenia). Two patients were unresponsive and had progressive disease following CAR-T therapy. Two patients with partial response had progressive disease during follow-up.

Conclusion Production efficacy and fulfilling the criteria of quality control were satisfactory for academic production. Response rates and toxicity profiles are acceptable for this heavily pretreated/refractory patient group. ISIKOK-19 cells appear to be a safe, economical, and efficient treatment option for CD19 positive tumors. The findings of this study need to be supported by the currently ongoing clinical trial of ISIKOK-19.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04206943

Funding Statement

All funding in the work was supported by Technology and Innovation Funding Programs Directorate (TEYDEB) and Acibadem Healthcare Group

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Production and treatment protocol was approved by the Ethical Committee of Acibadem University (Approval No: 2019-11/6) and by the review board of the Republic of Turkey Ministery of Health (Approval No:56733164/203)

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Funding statement: All funding in the work was supported by Technology and Innovation Funding Programs Directorate (TEYDEB) and Acibadem Healthcare Group

Data Availability

All data are available via Acibadem Hospital's electronic medical records system.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted September 26, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Preliminary Report of Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical Application
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Preliminary Report of Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical Application
Ebru Erdogan, Koray Yalcin, Cansu Hemsinlioglu, Aslihan Sezgin, Utku Seyis, Derya Dilek Kancagi, Cihan Tastan, Bulut Yurtsever, Raife Dilek Turan, Didem Cakirsoy, Selen Abanuz, Gozde Sir Karakus, Muhammer Elek, Huseyin Saffet Bekoz, Ali İhsan Gemici, Deniz Sargin, Mutlu Arat, Burhan Ferhanoglu, Ebru Pekguc, Serdar Ornek, Deram Buyuktas, Nur Birgen, Siret Ratip, Ercument Ovali
medRxiv 2021.09.23.21263731; doi: https://doi.org/10.1101/2021.09.23.21263731
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
Preliminary Report of Academic CAR-T (ISIKOK-19) Cell Clinical Trial in Turkey: Characterization of Product and Outcomes of Clinical Application
Ebru Erdogan, Koray Yalcin, Cansu Hemsinlioglu, Aslihan Sezgin, Utku Seyis, Derya Dilek Kancagi, Cihan Tastan, Bulut Yurtsever, Raife Dilek Turan, Didem Cakirsoy, Selen Abanuz, Gozde Sir Karakus, Muhammer Elek, Huseyin Saffet Bekoz, Ali İhsan Gemici, Deniz Sargin, Mutlu Arat, Burhan Ferhanoglu, Ebru Pekguc, Serdar Ornek, Deram Buyuktas, Nur Birgen, Siret Ratip, Ercument Ovali
medRxiv 2021.09.23.21263731; doi: https://doi.org/10.1101/2021.09.23.21263731

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Hematology
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1096)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9767)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2308)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1559)
  • Health Policy (736)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (503)
  • Infectious Diseases (except HIV/AIDS) (11641)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (237)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2142)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (517)
  • Oncology (1176)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (267)
  • Psychiatry and Clinical Psychology (2180)
  • Public and Global Health (4657)
  • Radiology and Imaging (778)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (251)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)